However, post hoc analysis revealed a trend toward a statistically significant increase in IL-8 release following LPS treatment in PBMCs isolated from healthy controls (p = 0.0612), but not in RR-MS patients. This evidence concerns the gene CXCL8 and myeloid sarcoma.